Welcome to our dedicated page for Endra Life Sciences news (Ticker: NDRA), a resource for investors and traders seeking the latest updates and insights on Endra Life Sciences stock.
ENDRA Life Sciences Inc. reports developments in thermoacoustic biomarker imaging, including its TAEUS® Liver device for measuring liver fat in steatotic liver disease, MASLD and MASH. Company news commonly covers clinical feasibility work comparing TAEUS measurements with MRI-PDFF, device repeatability and reproducibility, and business updates tied to operating results.
NDRA updates also include capital and treasury actions, such as private placement financing and a digital asset treasury strategy involving HYPE token holdings and staking. Corporate news has included strategic-review announcements and Nasdaq listing-compliance matters.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) will report financial results for the first quarter of 2024 on May 14, 2024. The company will hold a conference call and webcast to discuss the results and recent corporate developments. Participants can pre-register for the call for immediate access.
ENDRA Life Sciences Inc. (NASDAQ: NDRA) has strengthened its intellectual property with the issuance of five new international patents, including three in Europe and two in China. This brings ENDRA's IP portfolio to a milestone of 80 issued patents worldwide, protecting its Thermo Acoustic Enhanced UltraSound (TAEUS®) technology. The patents cover innovative solutions for providing RF energy to tissue, determining material types, and monitoring tissue temperature during surgical procedures, expanding the application of TAEUS technology.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.